Navigation Links
Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
Date:10/2/2009

MOUNTAIN VIEW, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that company management will present a corporate overview during the Fourth Annual JMP Securities Healthcare Focus Conference, being conducted at the New York Palace Hotel in New York. This corporate overview will be webcast live on Tuesday, October 6, 2009 at 10:30 a.m. Eastern Time.

To access the live presentation via the Web, please go to the direct conference link located at www.wsw.com/webcast/jmp9/alxa/ or at the Alexza Investor Relations tab at www.alexza.com.

A replay of the Webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting a New Drug Application submission in early 2010.

Alexza has completed an
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
2. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
3. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
4. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
5. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
6. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
7. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
8. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
9. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
10. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
11. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... N.J. , July 30, 2015  Unichem Pharmaceuticals ... recalling one lot of Hydrochlorothiazide tablets 25 mg 1000-count ... initiated as a precautionary measure due to the identification ... the product. The risk associated with ... tablet is the increased probability of experiencing Clopidogrel,s side ...
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) ... of 2015. Key results include: , Total ... of 2014 to $5,370 million, with 6 percent ... (etanercept), Prolia ® (denosumab), Sensipar ® ... ® (denosumab). Unfavorable changes in foreign exchange ...
(Date:7/30/2015)... THOUSAND OAKS, Calif. , July 30, 2015  Amgen ... Fred Hassan , partner and managing director of Warburg Pincus ... "We are pleased to welcome Fred Hassan and ... to the Amgen Board," said Robert A. Bradway , ... expertise and commitment to innovation will serve Amgen well." ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3
(Date:8/3/2015)... Miami, Florida (PRWEB) , ... August 03, 2015 , ... ... neuropathy pain accompanied by tissue injury caused by diabetes after many years of suffering ... work many times, and he didn’t want to ask for extra time off or ...
(Date:8/3/2015)... ... ... The American Institute of Architects (AIA) and ... a wide range of initiatives ranging from code development and compliance to sustainability ... membership, consisting of practicing design professionals, code officials, and the building industry representatives, ...
(Date:8/2/2015)... ... ... A new Phase I research study is looking at a vaccine that hopes ... G. Lucas, M.D. , chief of the division of pediatric hematology/oncology and stem cell ... Hospital and in the UofL Department of Pediatrics . Patients are currently ...
(Date:8/1/2015)... ... August 02, 2015 , ... AlignLife Office Coordinator Heather Pugh ... of care for patients at this natural health care center in Winamac. , "Oftentimes ... Heal said. "Heather's role is vital to our approach because we want to focus ...
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins are ... and women often causing pain and discomfort. Those who spend a lot of time ... Northeast Houston Vein Center is doing what it can to create awareness and provide ...
Breaking Medicine News(10 mins):Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3
... the nation,s leading,supplier of replacement medical repair parts for ... companies in Ohio by the Case Western,Weatherhead School of ... growth rate exceeding 1000% and has won the award ... clearly one of our region,s most prestigious,honors," said PartsSource ...
... could yield targeted treatments for leukemia, bone marrow transplants ... of all human blood cells has been identified by ... to new treatments for blood cancers and other blood ... progenitor, is the initial offspring of a blood-forming stem ...
... Inc.,(NYSE: BMR ) today announced that its board ... $0.31 per share of common stock. The,dividend is equivalent ... BioMed also announced that its board of directors ... company,s 7.375% Series A Cumulative,Redeemable Preferred Stock for the ...
... WASHINGTON, Dec. 12 Speaker Nancy Pelosi,Majority Leader Steny ... Rahm Emanuel held a news conference late this afternoon ... news conference, President,Bush vetoed the bill. Below are the ... that later today that the President,will veto the SCHIP ...
... experts say recall shouldn,t be health threat , , WEDNESDAY, ... 1.2 million doses of a common childhood vaccine due ... vaccine does not pose a health threat, U.S. health ... recalled two lots of the Haemophilus influenzae ...
... A new school curriculum,that counters abuse of prescription ... a press conference today in Washington, D.C. The,curriculum ... as presentations,for parents. This curriculum was created by ... and expertise of law enforcement,officials; the Pharmaceutical Research ...
Cached Medicine News:Health News:BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends 2Health News:Pelosi on Bush Veto of SCHIP: 'Democrats Will Not Rest Until 10 Million Children Have Access to Health Care' 2Health News:Common Infant Vaccine Recalled 2Health News:Common Infant Vaccine Recalled 3Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 2Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 3Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: